Caplight Logo









Immorna

Private
HangzhouHealthcare & Life Sciences

Last Round

Grant

Aug 26, 2024

Total Funding Raised

$118.8M

Company Overview

Immorna is a biotechnology company that develops mRNA-based therapeutics and vaccines for cancer immunotherapy, infectious diseases, and rare genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Pharma Supply Chain, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

self-replicating RNAsrRNAlipid nanoparticlesLNPsRNA therapeuticscontract development and manufacturingCDMOcircular RNAcircRNARNA vaccinescancer immunotherapyRNA manufacturingthermostable formulationdrug delivery systemsmRNA platformrare genetic diseases

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Immorna Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Immorna Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
GrantAug 26, 2024
Series A ExtensionFeb 27, 2023
Series AFeb 1, 2021
View all Funding Rounds

Immorna Investors

Notable investors and investment history

InvestorRounds
Zheshang Venture CapitalSeries A Extension, Series A
Co-Win VenturesSeries A Extension, Series A
Tigeryeah CapitalSeries A Extension
The Bill & Melinda Gates Foundation TrustGrant
华创资本Series A Extension, Series A
View all Investors

Immorna Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Immorna Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Immorna's valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou
Employee Range21
Year Founded2019
Last FundingAug 26, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.